Wolf D - Search Results

1

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors.

Valent P, Hadzijusufovic E, Schernthaner GH, Wolf D, Rea D, le Coutre P. Valent P, et al. Among authors: wolf d. Blood. 2015 Feb 5;125(6):901-6. doi: 10.1182/blood-2014-09-594432. Epub 2014 Dec 18. Blood. 2015. PMID: 25525119 Free article.

2

Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform.

Valent P, Lion T, Wolf D, Sillaber C, Agis H, Petzer A, Lang A, Kalhs P, Geissler D, Greil R, Linkesch W, Burgstaller S, Thaler J, Gastl G. Valent P, et al. Among authors: wolf d. Wien Klin Wochenschr. 2008;120(21-22):697-709. doi: 10.1007/s00508-008-1100-8. Wien Klin Wochenschr. 2008. PMID: 19116712

3

First annual report of the Austrian CML registry.

Schmidt S, Wolf D, Thaler J, Burgstaller S, Linkesch W, Petzer A, Fridrik M, Lang A, Agis H, Valent P, Krieger O, Walder A, Korger M, Schlögl E, Sliwa T, Wöll E, Mitterer M, Eisterer W, Pober M, Gastl G; ASHO CML registry. Schmidt S, et al. Among authors: wolf d. Wien Klin Wochenschr. 2010 Oct;122(19-20):558-66. doi: 10.1007/s00508-010-1450-x. Epub 2010 Oct 11. Wien Klin Wochenschr. 2010. PMID: 20936366

4

Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable?

Rudzki J, Wolf D. Rudzki J, et al. Among authors: wolf d. Expert Rev Hematol. 2011 Apr;4(2):153-9. doi: 10.1586/ehm.11.9. Expert Rev Hematol. 2011. PMID: 21495925

5

Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.

Valent P, Gastl G, Geissler K, Greil R, Hantschel O, Lang A, Linkesch W, Lion T, Petzer AL, Pittermann E, Pleyer L, Thaler J, Wolf D. Valent P, et al. Among authors: wolf d. Crit Rev Oncol Hematol. 2012 Jun;82(3):370-7. doi: 10.1016/j.critrevonc.2011.08.002. Epub 2011 Sep 7. Crit Rev Oncol Hematol. 2012. PMID: 21903413 Review.

6

The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo.

Heine A, Held SA, Daecke SN, Wallner S, Yajnanarayana SP, Kurts C, Wolf D, Brossart P. Heine A, et al. Among authors: wolf d. Blood. 2013 Aug 15;122(7):1192-202. doi: 10.1182/blood-2013-03-484642. Epub 2013 Jun 14. Blood. 2013. PMID: 23770777 Free article.

7

Advances in immunotherapy of chronic myeloid leukemia CML.

Held SA, Heine A, Mayer KT, Kapelle M, Wolf DG, Brossart P. Held SA, et al. Curr Cancer Drug Targets. 2013 Sep;13(7):768-74. doi: 10.2174/15680096113139990086. Curr Cancer Drug Targets. 2013. PMID: 23906051 Review.

8

Fatal progressive cerebral ischemia in CML under third-line treatment with ponatinib.

Mayer K, Gielen GH, Willinek W, Müller MC, Wolf D. Mayer K, et al. Among authors: wolf d. Leukemia. 2014 Apr;28(4):976-7. doi: 10.1038/leu.2013.320. Epub 2013 Oct 30. Leukemia. 2014. PMID: 24170029 No abstract available.

9

Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?

Heine A, Brossart P, Wolf D. Heine A, et al. Among authors: wolf d. Blood. 2013 Nov 28;122(23):3843-4. doi: 10.1182/blood-2013-10-531103. Blood. 2013. PMID: 24288410 Free article. No abstract available.

10

MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.

Agrawal M, Hanfstein B, Erben P, Wolf D, Ernst T, Fabarius A, Saussele S, Purkayastha D, Woodman RC, Hofmann WK, Hehlmann R, Hochhaus A, Müller MC. Agrawal M, et al. Among authors: wolf d. Leukemia. 2014 Jul;28(7):1478-85. doi: 10.1038/leu.2014.6. Epub 2014 Jan 10. Leukemia. 2014. PMID: 24472814

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,902 results

Search Page

Filters